Relapsed/Refractory Small Cell Lung Cancer
Oncology·MeSH: Small Cell Lung Carcinoma
Prevalence
6.0 / 100K
Incidence
8.0 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 4(1)
| Drug | Company |
|---|---|
| BMS-986525 | BRISTOL MYERS SQUIBB CO (BMY) |
Frequently asked questions
How many drugs are in development for Relapsed/Refractory Small Cell Lung Cancer?
BioSniper tracks 1 drug in development for Relapsed/Refractory Small Cell Lung Cancer across 1 company.
How many clinical trials target Relapsed/Refractory Small Cell Lung Cancer?
There are 1 clinical trial targeting Relapsed/Refractory Small Cell Lung Cancer tracked by BioSniper.
What is the prevalence of Relapsed/Refractory Small Cell Lung Cancer?
The estimated prevalence of Relapsed/Refractory Small Cell Lung Cancer is approximately 6.0 per 100,000 population.
Deep-dive into Relapsed/Refractory Small Cell Lung Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis